SOUTH SAN FRANCISCO, CA; LONDON, UK; and LA JOLLA, CA — Topcon Healthcare has announced a financial investment in Pangaea Data, a health AI company specializing in identifying untreated and under-treated patients at scale. The collaboration aims to accelerate the application of Pangaea’s clinically validated AI platform to address critical care gaps in eye health and systemic disease.
Pangaea’s Work
Pangaea Data’s platform automatically analyzes structured and unstructured patient records against clinical guidelines. This emulates a clinician’s manual review and uncovers patients who meet diagnostic or treatment criteria, but are not currently in a treatment or management process. Integrated directly into existing EHR and downstream scheduling systems, the platform enables real-time clinical action without disrupting workflows.
“We are thrilled to partner with Topcon Healthcare to scale our platform’s reach and improve timely diagnosis and treatment across eye care,” said Dr. Vibhor Gupta, Founder and CEO of Pangaea Data. “Together, we can empower providers to close care gaps while generating actionable insights for population health, discovery science and value-based care.”
Benefits of the Partnership
Through this partnership, Pangaea Data’s AI platform will leverage Topcon Healthcare’s Harmony digital health platform. The goal is to create a seamless interface for optometry and ophthalmology practices to identify patients needing follow-up or further evaluation. This includes patients with glaucoma, 50% of whom remain undiagnosed in the U.S.1 It also includes diabetic retinopathy, where more than one-third of diagnosed diabetics do not receive their recommended annual eye screening.2
“Pangaea Data’s unique ability to find missed patients using AI, and to do so without burdening clinicians, has powerful implications for eye care and beyond,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “This partnership supports our Healthcare from the Eye initiative, which uses ocular data and AI to transform how systemic and ocular diseases are detected and managed. We are proud to support Pangaea Data’s mission through this strategic investment.”
Pangaea Data’s platform has already demonstrated impact across multiple therapeutic areas. This includes pulmonology, cardiology, oncology, nephrology and infectious diseases. The company’s expansion into eye care through this partnership represents a significant step in advancing AI-driven clinical care globally.
References
1 Current Glaucoma Programs | Vision and Eye Health | CDC
2 Diabetic Retinopathy Screening – EyeWiki
Author
